Page 2 - Kronos Bio News Today

BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory

/PRNewswire/ -- DelveInsights Hematopoietic Stem Cell Transplantation Market Insights report includes a comprehensive understanding of current treatment...

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) COO Barbara Kosacz sold 10,676 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $1.18, for a total value of $12,597.68. Following the transaction, the chief operating officer now owns 928,966 shares of the company’s […]

Kronos Bio (NASDAQ:KRON – Free Report) had its price target cut by HC Wainwright from $9.00 to $2.50 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Separately, Piper Sandler dropped their price objective on Kronos Bio from $7.00 to $6.00 and set an […]

Christmas is fast approaching and the atmosphere on stock markets is rather joyful, with most indices in the green. Investors are cheering fresh data showing a slowdown in eurozone inflation in... -December 19, 2023 at 09:30 am EST - MarketScreener

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Kronos Bio Stock (NASDAQ: KRON) stock price, news, charts, stock research, profile.

Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the company has decided not to 

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New...